Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corgenix Medical (Corgenix) and Tulane University has reported a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF). The National Institutes of Health (NIH) has awarded a five-year contract totaling $15,224,927 to Tulane University for the expanded study.
Subscribe to our email newsletter
Reportedly, collaborating with Corgenix and Tulane in the contract are The Scripps Research Institute, the University of California at San Diego, Boston University, the Broad Institute, Harvard University, Autoimmune Technologies, Vybion and various partners in West Africa.
James Robinson, professor of pediatrics at the Tulane University School of Medicine and principle investigator of the program, said: “This study will result in a fundamental understanding of the mechanisms of antibody detection and antibody mediated neutralization of Lassa virus. This research has implications for the next generation of antibody based therapeutics against viral hemorrhagic fevers.”
Douglass Simpson, president and CEO of Corgenix, said: “We are extremely pleased to be part of this expanded collaboration and to have received the NIH contract. Building on the previous two grants for development of state-of-the-art diagnostic tests on multiple delivery platforms, this new contract will enable Tulane and the other collaborators to probe deeper into the mechanisms of the virus, which can ultimately lead to prevention of the disease.”